Skip to content

Released May 15, 2025, after the close

10-Q filed May 15, 2025, 45 days after period end · 0001683168-25-003705

Q1 2025 · 10-Q
Revenue—
Net Income-$6.32MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.32N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$6,365,584N/M
Operating Cash Flow-$4,618,740N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2025Q1 2024Q1 2023
Net Income-$6.32M-$8.30M-$5.27M
EPS Diluted-$0.32-$5.40—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR